At a glance
ClinicalIndex Comparison RecordN/ACompleted· 12 enrolled
Drug / intervention
Oral Glucose Tolerance Test (OGTT)other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Impact of Inflammation on Reward Circuits, Motivational Deficits and Negative Symptoms in Schizophrenia
In Brief
A clinical study evaluating Oral Glucose Tolerance Test (OGTT) for Schizophrenia. Completed, enrolled 12 participants across 6 sites.
Detailed Summary
This study will recruit persons with schizophrenia or schizoaffective disorder and will use an oral glucose tolerance test to test the hypothesis that insulin resistance drives inflammation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedJan 2019
Enrollment StartAug 2020
Primary CompletionMar 2022
TodayJul 2026
First PostedJan 28, 2019
Enrollment StartAug 31, 2020
Primary CompletionMar 1, 2022
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 7.4 years ago
Interventions
Oral Glucose Tolerance Test (OGTT)other
Participants will undergo a fasting blood draw for inflammatory and metabolic markers before a 75gm oral glucose tolerance test (OGTT) and at 1, 2 and 3 hours post-OGTT. Behavioral assessments will also be administered pre- and post-OGTT administration.